Page 6 - Agvhd News Today

Nelson J. Chao, MD, MBA, presents the patient profile of a 60-year-old man with chronic myeloid leukemia and graft-versus-host disease (GVHD) and shares his initial impressions.

The high dividend ETF duo of DIVI and UDIV could present an opportunity for agile current income as interest rate hikes loom.

Takeda (TSE:4502/NYSE:TAK) today announced late-breaking data from the Phase 3 GRAPHITE study presented at the 2023 Tandem Meetings, demonstrating vedolizumab achieved a statistically significant and clinically meaningful improvement in lower gastrointestinal (GI) aGvHD-free survival by Day 180 after allo-HSCT with no relevant differences in safety profile versus placebo.1

Top low-vol ETF stories of 2022 focused not only on low-vol strats, but also a standout theme in dividends, which may intrigue investors.

RGI-2001 was well tolerated and associated with a meaningful reduction in the incidence of severe acute GvHD REGiMMUNE Limited, a clinical-stage biopharmaceutical company developing innovative

Investors may want to consider an international dividends ETF like the Franklin International Low Volatility High Dividend Index ETF (LVHI).

Consider the stable yield ETF pairing of LVHD and LVHI for low-vol dividends in an up-and-down year for markets.

MONTREAL, Nov. 04, 2022 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation, announced today...

According to researchers at the Perelman School of Medicine at the University of Pennsylvania patients of Atrial fibrillation with VHD receiving apixaban had a lower risk for ischemic stroke or...

Investors often focus on growth versus value competition, but there are investment factors to consider.